South Carolina is currently home to 1159 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Charleston, Greenville, Columbia and Spartanburg. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Study to Evaluate Long-term Safety of Ecopipam Tablets in Children, Adolescents and Adults With Tourette's Disorder
NCT06021522
Recruiting
The primary objective of this study is to evaluate the long-term safety and tolerability of ecopipam tablets in children (greater than or equal to \[\>=\] 6 and less than \[\<\] 12 years of age), adolescents (\>=12 and \<18 years of age), and adults (\>=18 years of age) with Tourette's Syndrome (TS).
Gender:
ALL
Ages:
6 years and above
Trial Updated:
04/21/2025
Locations: Coastal Pediatric Research, Charleston, South Carolina
Conditions: Tourette Syndrome
Register for Updates
Neuropathic Pain and Operant Conditioning of Cutaneous Reflexes After SCI
NCT05492188
Recruiting
The purpose of the second part of the study is to examine the effect of reflex training in the leg to decrease neuropathic pain. For this, the researchers are recruiting 15 individuals with neuropathic pain due to spinal cord injury to participate in the reflex training procedure. The study involves approximately 50 visits with a total study duration of about 6.5 months (3 months for baseline and training phases followed by 1 month and 3 month follow-up visits).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/21/2025
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Spinal Cord Injuries, Neuropathic Pain, Neurological Injury, Pain
Register for Updates
Pembrolizumab Plus Olaparib in LA-HNSCC
NCT05366166
Recruiting
The purpose of this research study is to evaluate the effectiveness of using a combination of pembrolizumab and olaparib when given before and after standard chemoradiation therapy in treating locally advanced head and neck squamous cell carcinoma. Pembrolizumab and olaparib are drugs that are approved for head and neck cancer treatment. However, FDA has not approved the use of these two drugs together in treating head and neck cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/21/2025
Locations: Medical University of South Carolina (MUSC), Charleston, South Carolina
Conditions: Squamous Cell Carcinoma of Head and Neck
Register for Updates
Deliver-EE: Evaluating Effects of Meal Delivery
NCT05357261
Recruiting
This study will randomly assign 2,300 older adults on waiting lists at fourteen Meals on Wheels programs in Florida, Illinois, Maryland, Tennessee, Texas, North Carolina, South Carolina, and California into two groups who will receive: (a) daily delivery of meals, five days a week or (b) a shipment of 10 frozen meals, every two weeks. Researchers will examine participants' Medicare claims to understand if differences in healthcare utilization occur between the two groups within six months after... Read More
Gender:
ALL
Ages:
66 years and above
Trial Updated:
04/21/2025
Locations: Meals On Wheels - Anderson, Anderson, South Carolina
Conditions: Healthy
Register for Updates
Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial
NCT05334368
Recruiting
This is a 52-week, randomized, placebo-controlled, double-blind, parallel group, multicenter study of depemokimab in adults with uncontrolled HES receiving standard of care (SoC) therapy. The study will recruit patients with a confirmed diagnosis of HES and who are on stable HES therapy for at least 4 weeks prior to randomization (Visit 2). Eligible participants must have uncontrolled HES with a history of repeated flare (≥2 flares in the previous 12 months) and blood eosinophil count of ≥1,000... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/21/2025
Locations: GSK Investigational Site, Charleston, South Carolina
Conditions: Hypereosinophilic Syndrome
Register for Updates
Embolization of the Splenic Artery After Trauma
NCT05128955
Recruiting
Our aim is to conduct a multi-center, Bayesian, randomized clinical trial to evaluate the primary technical success of coils and vascular plugs for proximal splenic artery embolization in the setting of high-grade splenic trauma. The investigator has previously demonstrated the feasibility of such a study in a single center pilot trial.
Gender:
ALL
Ages:
15 years and above
Trial Updated:
04/21/2025
Locations: Prisma Health, Greenville, South Carolina
Conditions: High-grade Splenic Injuries
Register for Updates
Impact of Bromocriptine on Clinical Outcomes for Peripartum Cardiomyopathy
NCT05180773
Recruiting
The study will enroll 200 women newly diagnosed with peripartum cardiomyopathy within 5 months postpartum in a randomized placebo controlled trial of bromocriptine therapy to evaluate its impact on myocardial recovery and clinical outcomes. Given that bromocriptine prevents breastfeeding, an additional 50 women with peripartum cardiomyopathy excluded from the trial due to a desire to continue breastfeeding but meeting all other entry criteria will be followed in an observational cohort.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
04/19/2025
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Peripartum Cardiomyopathy, Postpartum
Register for Updates
Evaluate Efficacy, Safety and Tolerability of JTT-861 in Subjects With Heart Failure With Reduced Ejection Fraction
NCT06017609
Recruiting
This study will evaluate the efficacy, safety, tolerability and pharmacokinetics of JTT-861 administered once daily for 12 weeks in subjects with heart failure with reduced ejection fraction (HFrEF) who are on a stable, guideline-directed medical therapy for heart failure.
Gender:
ALL
Ages:
Between 30 years and 85 years
Trial Updated:
04/18/2025
Locations: Onsite Clinical Solutions, LLC, Rock Hill, South Carolina
Conditions: Chronic Heart Failure
Register for Updates
Nephrotic Syndrome Study Network
NCT01209000
Recruiting
Minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS), and Membranous nephropathy (MN), generate an enormous individual and societal financial burden, accounting for approximately 12% of prevalent end stage renal disease (ESRD) cases (2005) at an annual cost in the US of more than $3 billion. However, the clinical classification of these diseases is widely believed to be inadequate by the scientific community. Given the poor understanding of MCD/FSGS and MN biology, it is not s... Read More
Gender:
ALL
Ages:
80 years and below
Trial Updated:
04/18/2025
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Minimal Change Disease (MCD), Membranous Nephropathy, Glomerulosclerosis, Focal Segmental
Register for Updates
Preoperative 5-Day Radiotherapy for Soft Tissue Sarcoma
NCT06905132
Recruiting
The purpose of this research study is to preserve healthy tissue around the cancer on the arm(s) and/or leg(s) using Hypofractionated radiotherapy, while treating the cancer and preventing it from spreading to other areas of the body.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/17/2025
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Soft Tissue Sarcoma
Register for Updates
Study of ONCOFID-P-B (PACLITAXEL-HYALURONIC ACID)
NCT05024773
Recruiting
This is a phase III, single-arm, multicenter, international study to assess the efficacy and safety of ONCOFID-P-B following intravesical instillation in adult patients with histologically and cytologically confirmed CIS, with or without concomitant Ta-T1, who are unresponsive to BCG therapy and unwilling or unfit to undergo radical cystectomy. After providing written informed consent (in presence of an Independent Witness, if applicable), patients will receive an induction therapy consisting o... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/17/2025
Locations: Medical University of South Carolina (MUSC), Charleston, South Carolina
Conditions: Bladder Carcinoma in Situ (CIS)
Register for Updates
A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma
NCT06007690
Recruiting
The primary objective is to determine the safety and efficacy of belzupacap sarotalocan (bel-sar) compared to sham control in patients with primary indeterminate lesions (IL) or small choroidal melanoma (CM).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/15/2025
Locations: Retina Consultants of Carolina, Greenville, South Carolina
Conditions: Choroidal Melanoma, Indeterminate Lesions, Uveal Melanoma, Ocular Melanoma
Register for Updates